---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-26-000048"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2026-07-06T20:06:20+00:00"
generated_at: "2026-07-06T20:07:08.854534+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039

## Summary
- Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).
- Upfront payment of $1.25B; up to $750M in additional sales milestones for Star Therapeutics.
- VGA039 has Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease FDA designations.
- Transaction expected to be recorded as a one-time R&D expense in Q3 and full year 2026.
- VGA039 is in pivotal Phase 3 VIVID-6 study; potential first once-monthly subcutaneous prophylactic for VWD.

## SEC filing metadata
- accession: 0000879169-26-000048
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2026-07-06T20:06:20+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/0000879169-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/incy-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-26-000048
- JSON: https://secwatch.observer/filing/0000879169-26-000048.json
- Plain text: https://secwatch.observer/filing/0000879169-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.